Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SGN-40 · 2 trials · 2 indications
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| bortezomib | DRUG | Escalating intravenous repeating dose |
| SGN-40 | DRUG | Escalating intravenous repeating dose |
| rituximab | DRUG | Escalating intravenous repeating dose |
Inclusion Criteria: * Age ≥ 18 years * Documented pathologic diagnosis of multiple myeloma that has relapsed or failed to respond after treatment with at least one prior systemic therapy (other than corticosteroid monotherapy) * Measurable disease * At least one prior systemic therapy other than si...
Top 20 of 25 competitors
SGN-40 is an investigational oncology drug being studied for the treatment of Multiple Myeloma and Non-Hodgkin's Lymphoma. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
SGN-40 is being developed by Roche Holding AG, which trades under the ticker RHHBY. The drug is in Phase 1 clinical development for oncology indications.
SGN-40 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. Clinical trials for the drug have been completed.
SGN-40 has been studied in two completed Phase 1 clinical trials. NCT00556699 evaluated SGN-40 in combination with rituximab in patients with CD20-positive follicular and marginal zone B-cell Non-Hodgkin's Lymphoma. NCT00664898 studied SGN-40 in combination with bortezomib in patients with relapsed or refractory Multiple Myeloma.
SGN-40 is also known by other names, though specific alternative names have not been disclosed. It is an investigational drug being developed by Roche Holding AG for the treatment of Multiple Myeloma and Non-Hodgkin's Lymphoma.